The University of Chicago Header Logo

Connection

Mary Rinella to Liver

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Liver.
Mary Rinella
Connection Strength
2.567
Liver
  1. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
    View in: PubMed
    Score: 0.325
  2. Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417.
    View in: PubMed
    Score: 0.145
  3. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835.
    View in: PubMed
    Score: 0.139
  4. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273.
    View in: PubMed
    Score: 0.139
  5. Liver biopsy in living donors. Liver Transpl. 2002 Dec; 8(12):1123-5.
    View in: PubMed
    Score: 0.137
  6. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
    View in: PubMed
    Score: 0.127
  7. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
    View in: PubMed
    Score: 0.127
  8. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
    View in: PubMed
    Score: 0.124
  9. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 05; 73(5):2028-2038.
    View in: PubMed
    Score: 0.122
  10. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309.
    View in: PubMed
    Score: 0.117
  11. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
    View in: PubMed
    Score: 0.104
  12. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
    View in: PubMed
    Score: 0.096
  13. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.093
  14. Moderate Exercise for Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2016 08 01; 176(8):1083-4.
    View in: PubMed
    Score: 0.088
  15. Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014 Jun; 174(6):984-7.
    View in: PubMed
    Score: 0.076
  16. Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice. Gastroenterology. 2011 Oct; 141(4):1404-11, 1411.e1-2.
    View in: PubMed
    Score: 0.062
  17. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
    View in: PubMed
    Score: 0.062
  18. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008 May; 49(5):1068-76.
    View in: PubMed
    Score: 0.049
  19. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26; 392(24):2413-2424.
    View in: PubMed
    Score: 0.040
  20. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
    View in: PubMed
    Score: 0.040
  21. Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
    View in: PubMed
    Score: 0.039
  22. Body composition and muscle composition phenotypes in patients on waitlist and shortly after liver transplant - results from a pilot study. BMC Gastroenterol. 2024 Oct 09; 24(1):356.
    View in: PubMed
    Score: 0.039
  23. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.037
  24. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 03 01; 79(3):674-689.
    View in: PubMed
    Score: 0.036
  25. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023 Nov; 79(5):1110-1120.
    View in: PubMed
    Score: 0.036
  26. Editorial: global liver fat accumulation and global health-towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther. 2022 02; 55(4):489-490.
    View in: PubMed
    Score: 0.032
  27. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
    View in: PubMed
    Score: 0.032
  28. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
    View in: PubMed
    Score: 0.029
  29. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
    View in: PubMed
    Score: 0.028
  30. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.025
  31. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.